Home/Rare Diseases/Progeria

Multi-System

Progeria

Also called Hutchinson-Gilford progeria syndrome, HGPS

Progeria (Hutchinson-Gilford progeria syndrome, HGPS) is an extraordinarily rare autosomal dominant disorder caused by a point mutation (c.1824C>T) in the LMNA gene occurring de novo in almost all cases.

...active trials

Live from ClinicalTrials.gov

View trials below

About trials for Progeria

Clinical trials for progeria have evaluated farnesyltransferase inhibitors (lonafarnib), which showed modest benefit in slowing cardiovascular disease progression in early trials. The Progeria Research Foundation maintains information on clinical trials and provides support for affected families.

Try Match Me →

About Progeria

Progeria (Hutchinson-Gilford progeria syndrome, HGPS) is an extraordinarily rare autosomal dominant disorder caused by a point mutation (c.1824C>T) in the LMNA gene occurring de novo in almost all cases. The mutation produces a truncated lamin A protein that accumulates within the nuclear envelope, impairing nuclear function and causing cellular dysfunction. Affected children appear normal at birth but within the first year develop signs of rapidly accelerated aging: growth failure despite normal appetite, progressive alopecia with characteristic loss of eyebrows and lashes, distinctive facial features (micrognathia, prominent ears), and development of cardiovascular disease. Progressive atherosclerosis leads to myocardial infarction and stroke, typically in early teens. Children develop age-related diseases including hypertension, stiff joints, and skeletal abnormalities. Median lifespan is approximately 13-14 years, with death usually from cardiac events. The rapidity of aging makes progeria invaluable for studying aging biology.

Common Symptoms

  • Growth retardation and failure to thrive despite normal appetite
  • Progressive alopecia (hair loss) and loss of eyebrows
  • Distinctive facial features: micrognathia, prominent ears
  • Progressive cardiovascular disease and hypertension
  • Atherosclerosis and increased stroke risk
  • Skeletal abnormalities including stiff joints and hip/knee problems

Who It Affects

Autosomal dominant disorder, almost always due to de novo LMNA mutations. Median age of death about 13-14 years, usually from myocardial infarction or stroke. No ethnic predisposition. Affects males and females equally.

Getting Involved in Clinical Trials

Clinical trials for progeria have evaluated farnesyltransferase inhibitors (lonafarnib), which showed modest benefit in slowing cardiovascular disease progression in early trials. The Progeria Research Foundation maintains information on clinical trials and provides support for affected families. Current management is symptomatic, focusing on cardiovascular risk factor management and monitoring for complications. Recent drug combinations including lonafarnib have shown improved efficacy. Research into progeria has provided valuable insights into aging and cardiovascular disease. Discuss with your cardiologist and geneticist about clinical trial eligibility and emerging therapies that might extend lifespan and quality of life.

Trusted Sources

Active Clinical Trials for Progeria

Finding trials for Progeria...

Related Multi-System Conditions

Multi-System

Sarcoidosis

Sarcoidosis is an inflammatory disease characterized by formation of granulomas (clusters of immune cells) in multiple o...

Multi-System

Tuberous Sclerosis

Tuberous sclerosis is an autosomal dominant genetic disorder caused by mutations in TSC1 or TSC2 genes, resulting in dys...

Multi-System

Epidermolysis Bullosa

Epidermolysis bullosa is a group of rare genetic blistering disorders caused by mutations affecting proteins anchoring t...